Clinical EfficacyA published clinical case series showed Arakoda displayed an 80% cure rate in patients with persistent, relapsing babesiosis who had failed previous treatments.
Regulatory ApprovalArakoda was granted FDA Orphan Drug Designation for the treatment of babesiosis, enhancing its potential market value for a rare disease.
Sales GrowthArakoda sales continue to grow, with net product revenues reaching $607,574, a significant increase from $253,573.